Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 8/20 | 0.77 |
| ▸ | LMNA | P02545 | 8/20 | 0.77 |
| ▸ | SERPINA6 | P08185 | 7/20 | 0.77 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.77 |
| ▸ | BLM | P54132 | 4/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.77 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.77 |
| ▸ | PGR | P06401 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | HTR2B | P41595 | 1/20 | 0.72 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.65 |
| ▸ | TSHR | P16473 | 5/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18891198 | 1.00 | SHBG (0.77) | SHBGLMNASERPINA6NR3C1SMN1; SMN2 | |
| SCHEMBL14150039 | 1.00 | SHBG (0.77) | SHBGLMNASERPINA6NR3C1SMN1; SMN2 | |
| SCHEMBL18891189 | 1.00 | SHBG (0.77) | SHBGLMNASERPINA6NR3C1SMN1; SMN2 | |
| SCHEMBL5907026 | 0.90 | SHBG (0.72) | SHBGLMNASERPINA6NR3C1SMN1; SMN2 | |
| SCHEMBL27046839 | 0.89 | SHBG (0.70) | SHBGLMNASERPINA6NR3C1SMN1; SMN2 | |
| Hydroxyprogesterone SCHEMBL23456341 | 0.87 | LMNA (1.00) | SHBGLMNASERPINA6NR3C1SMN1; SMN2 | |
| Hydroxyprogesterone SCHEMBL18261234 | 0.87 | LMNA (1.00) | SHBGLMNASERPINA6NR3C1SMN1; SMN2 | |
| Hydroxyprogesterone SCHEMBL3931615 | 0.87 | LMNA (1.00) | SHBGLMNASERPINA6NR3C1SMN1; SMN2 | |
| Hydroxyprogesterone SCHEMBL14546356 | 0.87 | LMNA (1.00) | SHBGLMNASERPINA6NR3C1SMN1; SMN2 | |
| Hydroxyprogesterone SCHEMBL14523053 | 0.87 | LMNA (1.00) | SHBGLMNASERPINA6NR3C1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4677063-A1 | METHODS FOR GENERATING ENDOMETRIUM ASSEMBLOIDS | Babraham Institute (GB) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024184624-A1 | METHODS FOR GENERATING ENDOMETRIUM ASSEMBLOIDS | BABRAHAM INSTITUTE (GB) | 2024-09-12 | — | — | WO | disclosed |
| US-20220153776-A1 | ANTAGONISTS OF CB1 RECEPTOR | INST NAT SANTE RECH MED (FR) | 2022-05-19 | — | — | US | disclosed |
| EP-3170501-B1 | ANTAGONISTS OF CB1 RECEPTOR | INST NAT SANTE RECH MED (FR) | 2020-07-08 | — | — | EP | disclosed |
| US-20190071465-A1 | ANTAGONISTS OF CB1 RECEPTOR | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-07 | — | — | US | disclosed |
| US-10150793-B2 | Antagonists of CB1 receptor | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-12-11 | — | — | US | disclosed |
| US-10040816-B2 | Antagonists of CB1 receptor | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-08-07 | — | — | US | disclosed |
| EP-3170501-A1 | ANTAGONISTS OF CB1 RECEPTOR | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-05-24 | — | — | EP | disclosed |
| US-20160145294-A1 | Antagonists of CB1 Receptor | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-05-26 | — | — | US | disclosed |
| US-20160030449-A1 | TRANSDERMAL CREAM | THERAPEUTICSMD, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160015707-A1 | METHOD OF PROMOTING REMYELINATION | UNIV CASE WESTERN RESERVE (US) | 2016-01-21 | — | — | US | disclosed |
| EP-2709631-A1 | ANTAGONISTS OF CB1 RECEPTOR | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012160006-A1 | ANTAGONISTS OF CB1 RECEPTOR. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2012-11-29 | — | — | WO | disclosed |
| EP-0680970-B1 | Medrogestone | AMERICAN HOME PROD (US) | 2000-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030449-A1 | TRANSDERMAL CREAM | PGR, PGRMC2, CYP19A1 | SHBG 6/4885LMNA 278/4885SERPINA6 271/4885 |
| US-20160015707-A1 | METHOD OF PROMOTING REMYELINATION | CHAT, PMP22, MAG | SHBG 4727/4885LMNA 1763/4885SERPINA6 3200/4885 |
| US-10150793-B2 | Antagonists of CB1 receptor | CNR2, CNR1, GPR18 | SHBG 593/4885LMNA 4593/4885SERPINA6 3094/4885 |
| US-20190071465-A1 | ANTAGONISTS OF CB1 RECEPTOR | CNR2, CNR1, GPR18 | SHBG 593/4885LMNA 4593/4885SERPINA6 3094/4885 |
| US-10040816-B2 | Antagonists of CB1 receptor | CNR2, CNR1, GPR18 | SHBG 593/4885LMNA 4593/4885SERPINA6 3094/4885 |
| US-20160145294-A1 | Antagonists of CB1 Receptor | CNR2, CNR1, GPR18 | SHBG 593/4885LMNA 4593/4885SERPINA6 3094/4885 |
| US-20220153776-A1 | ANTAGONISTS OF CB1 RECEPTOR | CNR2, CNR1, GPR18 | SHBG 593/4885LMNA 4593/4885SERPINA6 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.